TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$137 Million


Follow-on Offering

Bookrunner, March 2018

GlycoMimetics is a clinical stage biotechnology company that utilizes novel and proprietary glycobiology technology to develop treatments for diseases with high unmet needs.The Company is developing its lead drug candidate, rivipansel, for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company has entered into a collaboration with Pfizer for the further development and potential commercialization of rivipansel worldwide. Rivipansel is currently in a Phase 3 trial and has received fast track designation, as well as orphan drug designation from the FDA in the U.S. and from the EMA, in the EU